Welcome to our dedicated page for Conavi Medical news (Ticker: CNVIF), a resource for investors and traders seeking the latest updates and insights on Conavi Medical stock.
Conavi Medical Corp. reports developments tied to its commercial-stage medical device business in cardiovascular imaging. The company designs, manufactures and markets technologies used to guide minimally invasive cardiovascular procedures, including a next-generation hybrid intravascular imaging system that combines intravascular ultrasound and optical coherence tomography in a single platform.
Recurring news themes include FDA 510(k) clearance, U.S. commercialization preparation, clinical and academic publications on hybrid IVUS-OCT imaging, operational and financial results, equity financing, non-dilutive funding agreements, leadership changes, investor conference participation and healthcare technology recognition.
Conavi Medical (OTCQB: CNVIF) will present at the Planet MicroCap Showcase: TORONTO in partnership with MicroCapClub on Wednesday, October 22, 2025 at 9:30 AM EST at the Arcadian Loft in Downtown Toronto.
Tom Looby, Chief Executive Officer, will host the presentation and take questions. A live webcast will be available and all company webcasts will be archived on the event platform under the Agenda tab. Investors may register to attend and request 1x1 in-person meetings at the conference venue.
Conavi Medical (OTCQB: CNVIF) has submitted its next-generation Novasight Hybrid™ IVUS/OCT intravascular imaging system to the FDA for 510(k) clearance. The system uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in a single integrated platform for coronary applications.
Key improvements include enhanced image quality, simplified user interface, improved cath lab workflow, and increased reliability. The company anticipates FDA clearance during H1 2026 and is preparing for US commercial launch. The coronary intravascular imaging market is projected to exceed $1 billion USD by 2028, supported by recent class IA guidelines in both US and Europe recommending IVUS or OCT for PCI procedural guidance.
Conavi Medical (OTCQB:CNVIF), a medical device company specializing in cardiovascular imaging technology, reported its fiscal Q3 2025 results and provided key operational updates. The company remains on track to submit its 510(k) application for the Novasight Hybrid™ system to the FDA in Q3 2025, targeting a commercial launch in H1 2026.
Financial highlights include a significant reduction in operating loss to $4.6M from $8.9M year-over-year, and improved cash position of $11.3M following a $20M equity offering completed in April. Revenue was $63,000, down from $401,000 in the prior year, reflecting the company's focus on next-generation product development.
Operational achievements include successful validation testing with leading cardiologists and a notable publication in JSCAI validating their hybrid IVUS/OCT imaging approach.
Conavi Medical (OTCQB: CNVIF) announced the publication of a significant case report in the Journal of the Society for Cardiovascular Angiography & Interventions featuring their Novasight™ Hybrid IVUS-OCT System. The case report demonstrates how the system's dual imaging capabilities led to superior diagnosis and treatment in a complex coronary case.
The study highlighted how the system correctly identified a plaque rupture that was initially misdiagnosed as calcification through traditional angiography. The technology combines high-resolution OCT imaging with IVUS anatomical reference points, enabling precise stent placement. CEO Thomas Looby confirmed the company's next-generation Novasight™ Hybrid System is on track for FDA 510(k) submission in Q3 2025.
Conavi Medical (OTCQB: CNVIF) highlights a significant study published in The American Journal of Cardiology regarding intracoronary imaging (ICI) during percutaneous coronary interventions (PCI). The study, analyzing over 1.8 million patient records, reveals that only 13.5% of patients received image-guided PCI by 2020, despite its proven benefits.
The company's Novasight Hybrid System, which uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) in a single platform, addresses key adoption barriers identified in the study. The system provides co-registered imaging in real-time, streamlining workflow and reducing procedural complexity while supporting recent Class IA recommendations in the 2024 ESC and 2025 ACC/AHA guidelines for complex PCI cases.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) announced that its Novasight Hybrid™ System has been awarded "Product Innovation of the Year" at the 2025 Minnesota Manufacturing Awards. The Novasight system is pioneering as the first commercial device to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) technologies for simultaneous, co-registered imaging of coronary arteries. This innovative technology provides interventional cardiologists with comprehensive insights during complex coronary procedures.
The award, presented by the Minneapolis/St. Paul Business Journal, recognizes Conavi's collaboration with Minnesota-based Minnetronix Medical. The company and its technology will be featured in a special publication on July 18, 2025.
Conavi Medical (TSXV: CNVI) (OTCQB: CNVIF), a commercial stage medical device company specializing in imaging technologies for minimally invasive cardiovascular procedures, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference.
CEO Thomas Looby will present on Tuesday, May 6, 2025, at 3:00 p.m. Eastern Time at the Metro Toronto Convention Centre. The presentation will be accessible via webcast, with replay available for 90 days on Conavi's Investor Relations website.
The conference facilitates connections between U.S., Canadian, and international investors interested in Canadian healthcare sector developments, offering corporate updates through presentations and private meetings with leading public and private companies.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) held its annual general meeting on March 31, 2025, with 30,075,712 common shares voted, representing 67.97% of outstanding shares. Key outcomes include:
- Election of seven directors: Thomas Looby, Aaron Davidson, Craig Podolsky, Robert D. Mitchell, Susan Allen, Cathy Steiner, and Anthony J. Giovinazzo
- Appointment of PricewaterhouseCoopers LLP as auditors
- Approval of amendments to the Omnibus Equity Incentive Plan, removing restrictions on insider participation
The plan maintains its maximum share issuance limit of 8,850,017 common shares (20% of outstanding shares as of October 11, 2024). The amendments await TSXV approval, and options granted under the modified plan cannot be exercised until approval is received.